İçeriğe geç
akaturk Akademik ölçüm

Akademisyen profili · PROFESÖR

LEVENT KABASAKAL

İSTANBUL ÜNİVERSİTESİ-CERRAHPAŞA

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Nükleer Tıp
  • CERRAHPAŞA TIP FAKÜLTESİ
  • DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Makale YÖKSİS 54
Proje 0
Kitap 0
Bildiri 0
Patent 0
Sanatsal 0
Scopus (SJR)
Q1 19 Q2 18 Q3 10 Q4 1
WoS (JCR)
Q1 20 Q2 1 Q3 15 Q4 15
TR Index 6 makale

Scopus (SJR)

WoS (JCR)

TR Index

6 makale

Toplam 54 yayın

Makaleler

  1. 2025 The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies European Journal of Nuclear Medicine and Molecular Imaging DOI 10.1007/s00259-025-07597-1
  2. 2025 External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-specific Membrane Antigen Positron Emission Tomography–based PRIMARY Score European Urology Open Science DOI 10.1016/j.euros.2025.10.020
  3. 2025 Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance European Journal of Nuclear Medicine and Molecular Imaging DOI 10.1007/s00259-025-07645-w
  4. 2025 [177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach European Journal of Nuclear Medicine and Molecular Imaging DOI 10.1007/s00259-025-07258-3
  5. 2025 Cancer Integrin Imaging with [68Ga]Ga-Trivehexin PET/CT for a Patient with Breast Cancer and Neuroendocrine Neoplasm: A Case of Both (18F)FDG PET/CT and [68Ga]Ga-DOTATATE Positive but Integrin avβ6 Negative Lesion on [68Ga]Ga-Trivehexin PET Molecular Imaging and Radionuclide Therapy DOI 10.4274/mirt.galenos.2024.60320
  6. 2024 Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance World Journal of Nuclear Medicine DOI 10.1007/s00259-023-06556-y
  7. 2024 Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer World Journal of Nuclear Medicine DOI 10.3390/jcm13164585
  8. 2024 Revision of the Histopathological Examination Following 68Ga- DOTA-FAPI-04 PET/CT of a Breast Tumor Diagnosed as Invasive Ductal Carcinomatosis Molecular Imaging and Radionuclide Therapy DOI 10.4274/mirt.galenos.2024.89106
  9. 2023 Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance Springer Science and Business Media LLC DOI 10.1007/s00259-023-06556-y
  10. 2023 Differentiated Thyroid Cancer in Children and Adolescents: Clinicopathological Characteristics of 32 Patients Followed up in our Pediatric Endocrinology Unit Kare Publishing DOI 10.14744/SEMB.2023.09216
  11. 2023 Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) Springer Science and Business Media LLC DOI 10.1007/s00259-023-06255-8
  12. 2023 Initial Findings on the Use of [<sup>225</sup>Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors Galenos Yayinevi DOI 10.4274/mirt.galenos.2023.38258
  13. 2023 A multi-institutional assessment of eye lens dose in nuclear medicine clinics NUCLEAR MEDICINE COMMUNICATIONS DOI 10.1097/MNM.0000000000001727
  14. 2022 The relationship between tumor mean standard uptake value (SUVmax) in preoperative PET/computed tomography and prognostic risk groups in endometrial cancer Ovid Technologies (Wolters Kluwer Health) DOI 10.1097/MNM.0000000000001654
  15. 2022 Almost Complete Response with a Single Administration Ac-225-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary MOLECULAR IMAGING AND RADIONUCLIDE THERAPY DOI 10.4274/mirt.galenos.2022.64497
  16. 2021 The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study European Journal of Nuclear Medicine and Molecular Imaging DOI 10.1007/s00259-021-05383-3
  17. 2021 Consensus on molecular imaging and theranostics in neuroendocrine neoplasms European Journal of Cancer DOI 10.1016/j.ejca.2021.01.008
  18. 2021 Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) European Journal of Nuclear Medicine and Molecular Imaging DOI 10.1007/s00259-020-04797-9
  19. 2021 Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT Annals of Nuclear Medicine DOI 10.1007/s12149-021-01627-2
  20. 2021 The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy Urology Journal DOI 10.22037/uj.v16i7.6165.

Akademisyenlere dön